Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies

Current Pharmaceutical Design

Volumn 15, Issue 23, 2009, Pages 2652-2664

  Kreitman, Robert J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 2; DIPHTHERIA TOXIN; DNA FRAGMENT; IMMUNOTOXIN; IMMUNOTOXIN BL 22; IMMUNOTOXIN LMB2; IMMUNOTOXIN RFB4(FV) PE38; INTERLEUKIN 2 RECEPTOR ALPHA; PSEUDOMONAS EXOTOXIN; RECOMBINANT FUSION TOXIN; RECOMBINANT IMMUNOTOXIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; B CELL LYMPHOMA; BINDING AFFINITY; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FEVER; DRUG HALF LIFE; DRUG PROTEIN BINDING; EDEMA; ESCHERICHIA COLI; GENE TARGETING; HAIRY CELL LEUKEMIA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; IMMUNOGENICITY; INTOXICATION; LEUKEMIA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; T CELL LEUKEMIA; THROMBOCYTOPENIA;

CLINICAL TRIALS AS TOPIC; DIPHTHERIA TOXIN; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTOXINS; LEUKOCIDINS; MODELS, BIOLOGICAL; RECOMBINANT PROTEINS; TOXINS, BIOLOGICAL;

EID: 70350148193     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788923949     Document Type: Review

References (190)

1. Yamaizumi M, Mekada E, Uchida T, Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 1978; 15: 245-50.
2. Endo Y, Mitsui K, Motizuki M, Tsurugi K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. J Biol Chem 1987; 262: 5908-12.
3. Eiklid K, Olsnes S, Pihl A. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp Cell Res 1980; 126: 321-6.
4. Strauss N, Hendee ED. The effect of diphtheria toxin on the metabolism of HeLa cells. J Exp Med 1959; 109(2): 145-63.
5. Moolten FL, Cooperband SR. Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells. Science 1970; 169(940): 68-70.
6. Masuho Y, Hara T, Noguchi T. Preparation of a hybrid of fragment Fab' of antibody and fragment A of diphtheria toxin and its cytotoxicity. Biochem Biophys Res Commun 1979; 90(1): 320-6.
7. Krolick KA, Villemez C, Isakson P, Uhr JW, Vitetta ES. Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc Natl Acad Sci USA 1980; 77(9): 5419-23.
8. Pastan I, Willingham MC, FitzGerald DJ. Immunotoxins. Cell 1986; 47(5): 641-8.
9. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989; 339: 394-7.
10. Zamboni M, Brigotti M, Rambelli F, Montanaro L, Sperti S. High pressure liquid chromatographic and fluorimetric methods for the determination of adenine released from ribosomes by ricin and gelonin. Biochem J 1989; 259: 639-43.
11. Carroll SF, Collier RJ. Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. J Biol Chem 1987; 262: 8707-11.
12. Van Ness BG, Howard JB, Bodley JW. ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products. J Biol Chem 1980; 255: 10717-01720.
13. Kreitman RJ. Getting plant toxins to fuse. Leukemia Res 1997; 21: 997-9.
14. Hwang J, FitzGerald DJ, Adhya S, Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 1987; 48: 129-36.
15. Allured VS, Collier RJ, Carroll SF, McKay DB. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0 Angstrom resolution. Proc Natl Acad Sci USA 1986; 83: 1320-4.
16. Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I. Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J Biol Chem 1989; 264: 14256-61.
17. Kreitman RJ, Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I. Properties of chimeric toxins with two recognition domains: Interleukin 6 and transforming growth factor α at different locations in Pseudomonas exotoxin. Bioconjug Chem 1992; 3: 63-8.
18. Kounnas MZ, Morris RE, Thompson MR, FitzGerald DJ, Strickland DK, Saelinger CB. The α2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem 1992; 267: 12420-3.
19. Chiron MF, Fryling CM, FitzGerald DJ. Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem 1994; 269: 18167-76.
20. Fryling C, Ogata M, FitzGerald D. Characterization of a cellular protease that cleaves Pseudomonas exotoxin. Infect Immun 1992; 60: 497-502.
21. 280 generates the enzymatically active fragment which translocates to the cytosol. J Biol Chem 1992; 267: 25396-401.
22. Chaudhary VK, Jinno Y, FitzGerald D, Pastan I. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci USA 1990; 87: 308-12.
23. Kreitman RJ, Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 1995; 307: 29-37.
24. Theuer C, Kasturi S, Pastan I. Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes. Biochemistry 1994; 33: 5894-900.
25. Theuer CP, Buchner J, FitzGerald D, Pastan I. The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion. Proc Natl Acad Sci USA 1993; 90: 7774-8.
26. Li M, Dyda F, Benhar I, Pastan I, Davies DR. The crystal structure of Pseudomonas aeruginosa exotoxin domain III with nicotinamide and AMP: Conformational differences with the intact exotoxin. Proc Natl Acad Sci USA 1995; 92(20): 9308-12.
27. Li M, Dyda F, Benhar I, Pastan I, Davies DR. Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: Implications for the activation process and for ADP ribosylation. Proc Natl Acad Sci USA 1996; 93(14): 6902-6.
28. Han XY, Galloway DR. Active site mutations of Pseudomonas aeruginosa exotoxin A - Analysis of the His(440) residue. J Biol Chem 1995; 270(2): 679-84.
29. Webb TR, Cross SH, McKie L, Edgar R, Vizor L, Harrison J, et al. Diphthamide modification of eEF2 requires a J-domain protein and is essential for normal development. J Cell Sci 2008; 121(Pt 19): 3140-5.
30. Jorgensen R, Merrill AR, Andersen GR. The life and death of translation elongation factor 2. Biochem Soc Trans 2006; 34: 1-6.
31. Brinkmann U, Brinkmann E, Gallo M, Pastan I. Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1. Proc Natl Acad Sci USA 1995; 92: 10427-31.
32. Keppler-Hafkemeyer A, Kreitman RJ, Pastan I. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Int J Cancer 2000; 87(1): 86-94.
33. Decker T, Oelsner M, Kreitman RJ, Salvatore G, Wang QC, Pastan I, et al. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia cells by Anti-CD22 immunotoxins. Blood 2004; 103(7): 2718-26.
34. Decker T, Wagner M, Oelsner M, Kreitman RJ, Pastan I, Peschel C, et al. Induction of cell cycle arrest and apoptosis in mantle cell lymphoma by recombinant immunotoxin BL22. Cancer Res 2004: Submitted.
35. r ∼6000 region of the toxin. J Biol Chem 1990; 265: 7331-7.
36. Uchida T, Pappenheimer AM, Jr., Harper AA. Reconstitution of diphtheria toxin from two nontoxic cross-reacting mutant proteins. Science 1972; 175: 901-3.
37. Uchida T, Pappenheimer AM, Jr., Greany R. Diphtheria toxin and related proteins I. Isolation and properties of mutant proteins serologically related to diphtheria toxin. J Biol Chem 1973; 248: 3838-44.
38. Choe S, Bennett MJ, Fujii G, Curmi PMG, Kantardjieff KA, Collier RJ, et al. The crystal structure of diphtheria toxin. Science 1992; 357: 216-22.
39. Williams DP, Wen Z, Watson RS, Boyd J, Strom TB, Murphy JR. Cellular processing of the interleukin-2 fusion toxin DAB486-IL-2 and efficient delivery of diphtheria fragment A to the cytosol of target cells requires Arg194. J Biol Chem 1990; 265(33): 20673-7.
40. Iwamoto R, Higashiyama S, Mitamura T, Taniguchi N, Klagsbrun M, Mekada E. Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity. EMBO J 1994; 13(10): 2322-30.
41. vanderSpek J, Cassidy D, Genbauffe F, Huynh PD, Murphy JR. An intact transmembrane helix 9 is essential for the efficient delivery of the diphtheria toxin catalytic domain to the cytosol of target cells. J Biol Chem 1994; 269: 21455-9.
42. Zhan H, Choe S, Huynh PD, Finkelstein A, Eisenberg D, Collier RJ. Dynamic transitions of the transmembrane domain of diphtheria toxin: disulfide trapping and fluorescence proximity studies. Biochemistry 1994; 33: 11254-63.
43. Cabiaux V, Mindell J, Collier RJ. Membrane translocation and channel-forming activities of diphtheria toxin are blocked by replacing isoleucine 364 with lysine. Infect Immun 1993; 61: 2200-2.
44. Kaul P, Silverman J, Shen WH, Blanke SR, Huynh PD, Finkelstein A, et al. Roles of Glu 349 and Asp 352 in membrane insertion and translocation by diphtheria toxin. Protein Sci 1996; 5(4): 687-92.
45. Papini E, Schiavo G, Tomasi M, Colombatti M, Rappuoli R, Montecucco C. Lipid interaction of diphtheria toxin and mutants with altered fragment B. 2. Hydrophobic photolabelling and cell intoxication. Eur J Biochem 1987; 169: 637-44.
46. Moskaug JO, Stenmark H, Olsnes S. Insertion of diphtheria toxin B-fragment into the plasma membrane at low pH. Characterization and topology of inserted regions. J Biol Chem 1991; 266: 2652-9.
47. Lemichez E, Bomsel M, Devilliers G, vanderSpek J, Murphy JR, Lukianov EV, et al. Membrane translocation of diphtheria toxin fragment A exploits early to late endosome trafficking machinery. Mol Microbiol 1997; 23(3): 445-57.
48. Wilson BA, Blanke SR, Reich KA, Collier RJ. Active-site mutations of diphtheria toxin. Tryptophan 50 is a major determinant of NAD affinity. J Biol Chem 1994; 269(37): 23296-301.
49. Bennett MJ, Eisenberg D. Refined structure of monomeric diphtheria toxin at 2.3 A resolution. Protein Sci 1994; 3: 1464-75.
50. Holbourn KP, Shone CC, Acharya KR. A family of killer toxins - Exploring the mechanism of ADP- ribosylating toxins. FEBS J 2006; 273(20): 4579-93.
51. Thorburn A, Thorburn J, Frankel AE. Induction of apoptosis by tumor cell-targeted toxins. Apoptosis 2004; 9(1): 19-25.
52. Kondo T, FitzGerald D, Chaudhary VK, Adhya S, Pastan I. Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain. J Biol Chem 1988; 263: 9470-5.
53. Kreitman RJ, Batra JK, Seetharam S, Chaudhary VK, FitzGerald DJ, Pastan I. Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: Relative importance of the two toxin disulfide bonds. Bioconjug Chem 1993; 4: 112-20.
54. Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng 1987; 1: 493-8.
55. Williams DP, Snider CE, Strom TB, Murphy JR. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 1990; 265(20): 11885-9.
56. Chaudhary VK, FitzGerald DJ, Pastan I. A proper amino terminus of diphtheria toxin is important for cytotoxicity. Biochem Biophys Res Commun 1991; 180: 545-51.
57. Studier FW, Moffatt BA. Use of bacteriophage T7 polymerase to direct selective expression of cloned genes. J Mol Biol 1986; 189: 113-30.
58. Chaudhary VK, Xu Y, FitzGerald D, Adhya S, Pastan I. Role of domain II of Pseudomonas exotoxin in the secretion into the periplasm and medium by Escherichia coli. Proc Natl Acad Sci USA 1988; 85: 2939-43
59. Bendel AE, Shao Y, Davies SM, Warman B, Yang CH, Waddick KG, et al. A recombinant fusion toxin targeted to the granulocytemacrophage colony-stimulating factor receptor. Leuk Lymphoma 1997; 25(3-4): 257.
60. Buchner J, Pastan I, Brinkmann U. A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem 1992; 205: 263-70.
61. Kreitman RJ, Pastan I. Making fusion toxins to target leukemia and lymphoma. In: Francis GE, Delgado C, Eds. Drug Targeting. 999 Riverview Dr/Ste 208/Totowa/NJ 07512-1165/USA: Humana Press Inc 2000; pp. 215-26.
62. Kreitman RJ, Pastan I. Purification and characterization of IL6PE4E, a recombinant fusion of interleukin 6 with Pseudomonas exotoxin. Bioconjug Chem 1993; 4(6): 581-5.
63. Kreitman RJ, Pastan I. Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either Pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells. Blood 1997; 90: 252-9.
64. Woo JH, Liu YY, Mathias A, Stavrou S, Wang Z, Thompson J, et al. Gene optimization is necessary to express a bivalent anti-human anti-T cell immunotoxin in Pichia pastoris. Protein Expr Purif 2002; 25(2): 270-82.
65. Woo JH, Liu JS, Kang SH, Singh R, Park SK, Su Y, et al. GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1) for phase I/II clinical trials. Protein Expr Purif 2008; 58(1): 1-11.
66. Kuzel TM, Li S, Eklund J, Foss F, Gascoyne R, Abramson N, et al. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497. Leuk Lymphoma 2007; 48(12): 2397-402.
67. Foss F. Clinical Experience With Denileukin Diftitox (ONTAK). Semin Oncol 2006; 33(1 Suppl 3): 11-6.
68. Frankel AE, Surendranathan A, Black JH, White A, Ganjoo K, Cripe LD. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer 2006; 106(10): 2158-64.
69. Davey RT, Jr., Boenning CM, Herpin BR, Batts DH, Metcalf JA, Wathen L, et al. Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J Infect Dis 1994; 170: 1180-8.
70. Goldberg MR, Heimbrook DC, Russo P, Sarosdy MF, Greenberg RE, Giantonio BJ, et al. Phase I clinical study of recombinant oncotoxin TP40 in superficial bladder cancer. Clin Cancer Res 1995; 1: 57-61.
71. Garland L, Gitlitz B, Ebbinghaus S, Pan H, deHaan H, Puri RK, et al. Phase I trial of intravenous IL-4 Pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J Immunother 2005; 28(4): 376-81.
72. Kreitman RJ, Puri RK, Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci USA 1994; 91: 6889-93.
73. Kreitman RJ, Puri RK, Pastan I. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. Cancer Res 1995; 55: 3357-63.
74. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of a recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high grade glioma. Clin Cancer Res 2000; 6(6): 2157-65.
75. Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, et al. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: Phase 1 study of final safety results. Neurosurgery 2007; 61(5): 1031-7; discussion 7-8.
76. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: Presentation of interim findings from ongoing phase 1 studies. In: Westphal M, Tonn JC, Ram Z, Eds. Local Therapies for Glioma: Present Status and Future Developments. Sachsenplatz 4-6/a-1201 Vienna/Austria: SpringerVerlag Wien 2003; pp. 105-11.
77. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: A report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007; 25(7): 837-44.
78. Frankel AE, Ramage J, Latimer A, Feely T, Delatte S, Hall P, et al. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials. Protein Expr Purif 1999; 16(1): 190-201.
79. Hotchkiss CE, Hall PD, Cline JM, Willingham MC, Kreitman RJ, Gardin J, et al. Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys. Toxicol Appl Pharmacol 1999; 158(2): 152-60.
80. Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colonystimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res 2002; 8(5): 1004-13.
81. Frankel A, McCubrey J, Miller MS, Delatte S, Ramage J, Kiser M, et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with acute phase chronic myeloid leukemia. Leukemia 2000; 14(4): 576-85.
82. Urieto JO, Liu T, Black JH, Cohen KA, Hall PD, Willingham MC, et al. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr Purif 2004; 33(1): 123-33.
83. Frankel A, Liu JS, Rizzieri D, Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma 2008; 49(3): 543-53.
84. Murphy JR, vanderSpek JC. Targeting diphtheria toxin to growth factor receptors. Semin Cancer Biol 1995; 6: 259-67.
85. Brinkmann U, Pai LH, FitzGerald DJ, Willingham M, Pastan I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci USA 1991; 88: 8616-20.
86. Brinkmann U, Reiter Y, Jung S, Lee B, Pastan I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci USA 1993; 90(16): 7538-42.
87. Reiter Y, Brinkmann U, Kreitman RJ, Jung S-H, Lee B, Pastan I. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry 1994; 33: 5451-9.
88. Reiter Y, Kreitman RJ, Brinkmann U, Pastan I. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide- stablized anti-Tac Fv fragment and truncated Pseudomonas exotoxin. Int J Cancer 1994; 58: 142-9.
89. Kodaka T, Uchiyama T, Ishikawa T, Kamio M, Onishi R, Itoh K, et al. Interleukin-2 receptor ??-chain (p70-75) expressed on leukemic cells from adult T cell leukemia patients. Jpn J Cancer Res 1990; 81: 902-8.
90. Yagura H, Tamaki T, Furitsu T, Tomiyama Y, Nishiura T, Tominaga N, et al. Demonstration of high-affinity interleukin-2 receptors on B-chronic lymphocytic leukemia cells: Functional and structural characterization. Blut 1990; 60: 181-6.
91. Kreitman RJ, Pastan I. Recombinant single-chain immunotoxins against T and B cell leukemias. Leuk Lymphoma 1994; 13: 1-10.
92. Robb RJ, Greene WC, Rusk CM. Low and high affinity cellular receptors for interleukin 2. J Exp Med 1984; 160: 1126-46.
93. Gazzola M, Collins NH, Tafuri A, Keever CA. Recombinant interleukin 3 induces interleukin 2 receptor expression on early myeloid cells in normal human bone marrow. Exp Hematol 1992; 20: 201-8.
94. Lorberboum-Galski H, Kozak RW, Waldmann TA, Bailon P, FitzGerald DJP, Pastan I. Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor. J Biol Chem 1988; 263: 18650-6.
95. Lorberboum-Galski H, FitzGerald D, Chaudhary V, Adhya S, Pastan I. Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli. Proc Natl Acad Sci USA 1988; 85: 1922-6.
96. 4Glu, a new chimeric protein cytotoxic to human activated T lymphocytes. J Biol Chem 1990; 265: 16311-7.
97. Bacha P, Williams DP, Waters C, Williams JM, Murphy JR, Strom TB. Interleukin 2 receptor-targeted cytotoxicity: Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med 1988; 167: 612-22.
98. Uchiyama TA, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 1981; 126: 1393-7.
99. Taniguchi T, Minami Y. The IL2/IL-2 receptor system: A current overview. Cell 1993; 73: 5-8.
100. Kreitman RJ, Bailon P, Chaudhary VK, FitzGerald DJP, Pastan I. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood 1994; 83: 426-34.
101. Kreitman RJ, Pastan I. Targeting Pseudomonas exotoxin to hematologic malignancies. Semin Cancer Biol 1995; 6: 297-306.
102. Robbins DH, Margulies I, Stetler-Stevenson M, Kreitman RJ. Hairy cell leukemia, a B-cell neoplasm which is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2). Clin Cancer Res 2000; 6(2): 693-700.
103. Decker T, Hipp S, Kreitman RJ, Pastan I, Peschel C, Licht T. Sensitization of B-CLL cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligonucleotides. Blood 2002: 1320-6.
104. Ohno N, Kreitman RJ, Saito T, Masamoto I, Uozumi K, Hanada S, et al. Augmentation of the activity of an immunotoxin, anti-Tac(Fv)-PE40KDEL, in T cell lines infected with human T cell leukemia virus type-I. Leuk Lymphoma 2002; 43(4): 885-8.
105. Kreitman RJ, Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo: Fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res 1998; 58(5): 968-75.
106. Kobayashi H, Kao CK, Kreitman RJ, Le N, Kim M, Brechbiel MW, et al. Pharmacokinetics of In-111- and I-125-labeled antiTac single-chain Fv recombinant immunotoxin. J Nuclear Med 2000; 41(4): 755-62.
107. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Waldmann TA, et al. Phase I trial of recombinant immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18: 1614-36.
108. Kreitman RJ, Wilson WH, Robbins D, Margulies I, Stetler-Stevenson M, Waldmann TA, et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999; 94: 3340-8.
109. Onda M, Kreitman RJ, Vasmatzis G, Lee B, Pastan I. Reduction of the nonspecific toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J Immunol 1999; 163: 6072-7.
110. Onda M, Willingham M, Wang Q, Kreitman RJ, Tsutsumi Y, Nagata S, et al. Inhibition of TNF alpha produced by Kupffer cells protects against the non-specific liver toxicity of immunotoxin anti- Tac(Fv)-PE38, LMB-2. J Immunol 2000; 165(12): 7150-6.
111. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood 1958; 13: 609-30.
112. Bouroncle BA. Thirty-five years in the progress of hairy cell leukemia. Leuk Lymphoma 1994; 14 Suppl 1: 1-12.
113. Bethel KJ, Sharpe RW. Pathology of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003; 16(1): 15-31.
114. Polliack A. Hairy cell leukemia: Biology, clinical diagnosis, unusual manifestations and associated disorders. Rev Clin Exp Hematol 2002; 6(4): 366-88; discussion 449-50.
115. Robbins BA, Ellison DJ, Spinosa JC, Carey CA, Lukes RJ, Poppema S, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 1993; 82(4): 1277-87.
116. Sausville JE, Salloum R, Sorbara L, Kingma DW, Raffeld M, Kreitman RJ, et al. Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol 2003; 119: 213-7.
117. Golomb HM, Catovsky D, Golde DW. Hairy cell leukemia: A clinical review based on 71 cases. Ann Intern Med 1978; 89(5 Pt 1): 677-83.
118. Habermann TM. Splenectomy, interferon, and treatments of historical interest in hairy cell leukemia. Hematol Oncol Clin North Am 2006; 20(5): 1075-86.
119. Zakarija A, Peterson LC, Tallman MS. Splenectomy and treatments of historical interest. Best Pract Res Clin Haematol 2003; 16(1): 57-68
120. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92(6): 1918-26.
121. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003; 21(5): 891-6.
122. Cheson BD, Sorensen JM, Vena DA, Montello MJ, Barrett JA, Damasio E, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: A report of 979 patients. J Clin Oncol 1998; 16(9): 3007-15.
123. Else M, Ruchlemer R, Osuji N, DelGiudice I, Matutes E, Woodman A, et al. Long remissions in hairy cell leukemia with purine analogs - A report of 219 patients with a median follow-up of 12.5 years. Cancer 2005; 104(11): 2442-8.
124. Grever MR. Pentostatin: Impact on outcome in hairy cell leukemia. Hematol Oncol Clin N Am 2006; 20(5): 1099+.
125. Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 1989; 7(2): 168-72.
126. Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study. J Clin Oncol 1995; 13(4): 974-82.
127. Maloisel F, Benboubker L, Gardembas M, Coiffier B, Divine M, Sebban C, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A french retrospective study of 238 patients. Leukemia 2003; 17(1): 45-51.
128. Johnston JB, Eisenhauer E, Wainman N, Corbett WEN, Zaentz SD, Daeninck P. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): A National Cancer Institute of Canada Study. Semin Oncol 2000; 27(2): 32-6.
129. Carbone A, Reato G, Di Celle PF, Lauria F, Foa R. Disease eradication in hairy cell leukemia patients treated with 2- chlorodeoxyadenosine {letter}. Leukemia 1994; 8(11): 2019-20.
130. Filleul B, Delannoy A, Ferrant A, Zenebergh A, Van Daele S, Bosly A, et al. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 1994; 8(7): 1153-6.
131. Arons E, Margulies I, Sorbara L, Raffeld M, Stetler-Stevenson M, Pastan I, et al. Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction. Clin Cancer Res 2006; 12(9): 2804-11.
132. Cawley JC, Burns GF, Hayhoe FG. A chronic lymphoproliferative disorder with distinctive features: A distinct variant of hairy-cell leukaemia. Leuk Res 1980; 4(6): 547-59.
133. Matutes E. Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol Oncol Clin N Amer 2006; 20(5): 1051+.
134. Sainati L, Matutes E, Mulligan S, de Oliveira MP, Rani S, Lampert IA, et al. A variant form of hairy cell leukemia resistant to alpha-interferon: Clinical and phenotypic characteristics of 17 patients. Blood 1990; 76(1): 157-62.
135. Matutes E, Oscier D, Montalban C, Berger F, CalletBauchu E, Dogan A, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008; 22(3): 487-95.
136. Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 2001; 15(1): 184-6.
137. Cessna MH, Hartung L, Tripp S, Perkins SL, Bahler DW. Hairy cell leukemia variant - Fact or Fiction. Am J Clin Pathol 2005; 123(1): 132-8.
138. Blasinska-Morawiec M, Robak T, Krykowski E, Hellmann A, Urbanska-Rys H. Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine - a report of three cases. Leuk Lymphoma 1997; 25(3-4): 381-5.
139. Tetreault SA, Robbins BA, Saven A. Treatment of hairy cell leukemia-variant with cladribine. Leuk Lymphoma 1999; 35(3-4): 347-54.
140. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003; 16(1): 41-56.
141. Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993; 82: 2624-33.
142. Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study. Blood 1995; 85: 3457-65.
143. Senderowicz AM, Vitetta E, Headlee D, Ghetie V, Uhr JW, Figg WD, et al. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann Intern Med 1997; 126(11): 882-5.
144. Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, et al. A phase I study of combination therapy with immunotoxins IgG-HD37- deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma [In Process Citation]. Clin Cancer Res 2000; 6(4): 1302-13.
145. Kreitman RJ, Hansen HJ, Jones AL, FitzGerald DJP, Goldenberg DM, Pastan I. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Res 1993; 53: 819-25.
146. Theuer CP, Kreitman RJ, FitzGerald DJ, Pastan I. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity. Cancer Res 1993; 53: 340-7.
147. Mansfield E, Chiron MF, Amlot P, Pastan I, FitzGerald DJ. Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells. Biochem Soc Trans 1997; 25: 709-14.
148. Mansfield E, Amlot P, Pastan I, FitzGerald DJ. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood 1997; 90: 2020-6.
149. Kreitman RJ, Wang QC, FitzGerald DJP, Pastan I. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by Cynomolgus monkeys. Int J Cancer 1999; 81: 148-55.
150. Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, Fitz-Gerald DJP, Pastan I. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) towards fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res 2000; 6: 1476-87.
151. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. New Engl J Med 2001; 345(4): 241-7.
152. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, Fitzgerald DJ, Wilson WH, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005; 23(27): 6719-29.
153. Tallman MS, Hakimian D, Kopecky KJ, Wheaton S, Wollins E, Foucar K, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2- deoxycoformycin and prediction of early relapse. Clin Cancer Res 1999; 5(7): 1665-70.
154. Moake JL. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Arch Pathol Lab Med 2002; 126(11): 1430-3.
155. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, FitzGerald DJP, Wilson WH, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009: In press.
156. Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I. Improved Cytotoxic activity towards cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 2002; 8(4): 995-1002.
157. Bang S, Nagata S, Onda M, Kreitman RJ, Pastan I. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 2005; 11(4): 1545-50.
158. Ho M, Kreitman RJ, Onda M, Pastan I. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem 2005; 280(1): 607-17.
159. Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 2008; 105(32): 11311-6.
160. Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, Fitz-Gerald DJ, et al. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 2008: In press.
161. Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res 2005; 11(10): 3879-88.
162. Callard RE, Smith CM, Worman C, Linch D, Cawley JC, Beverley PC. Unusual phenotype and function of an expanded subpopulation of T cells in patients with haemopoietic disorders. Clin Exp Immunol 1981; 43(3): 497-505.
163. Martin PJ, Hansen JA, Torok-Storb B, Moretti L, Press O, Storb R, et al. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transplant 1988; 3: 437-44.
164. Thompson J, Hu H, Scharff J, Neville DM, Jr. An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood. J Biol Chem 1995; 270(47): 28037-41.
165. Thompson J, Stavrou S, Weetall M, Hexham JM, Digan ME, Wang Z, et al. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion. Protein Eng 2001; 14(12): 1035-41.
166. Woo JH, Bour SH, Dang T, Lee YJ, Park SK, Andreas E, et al. Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1). Cancer Immunol Immunother 2008; 57(8): 1225-39.
167. Onda M, Nagata S, Fitzgerald DJ, Beers R, Fisher RJ, Vincent JJ, et al. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 2006; 177(12): 8822-34.
168. Roscoe DM, Jung SH, Benhar I, Pai L, Lee BK, Pastan I. Primate antibody response to immunotoxin: Serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin. Infect Immun 1994; 62(11): 5055-65.
169. Roscoe DM, Pai LH, Pastan I. Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins. Eur J Immunol 1997; 27(6): 1459-68.
170. Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Nat Acad Sci USA 2008; 105(32): 11311-6.
171. Stahnke B, Thepen T, Stocker M, Rosinke R, Jost E, Fischer R, et al. Granzyme B-H22(ScFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther 2008; 7(9): 2924-32.
172. Menzel C, Schirrmann T, Konthur Z, Jostock T, Dubel S. Human antibody RNase fusion protein targeting CD30(+) lymphomas. Blood 2008; 111(7): 3830-7.
173. Hursey M, Newton DL, Hansen HJ, Ruby D, Goldenberg DM, Rybak SM. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: A new generation of therapeutics. Leuk Lymphoma 2002; 43(5): 953-9.
174. Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM, Rybak SM. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: Potential for the treatment of non-Hodgkin lymphoma. Blood 2001; 97(2): 528-35.
175. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999; 93(11): 3678-84.
176. de Vetten MP, Jansen JH, van der Reijden BA, Berger MS, Zijlmans JMJM, Lowenberg B. Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjnugate (gemtuzumab ozogamicin, CMA-676). Br J Haematol 2000; 111: 277-9.
177. Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (Gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 2000; 14(8): 1436-43.
178. Nabhan C, Tallman MS. Early phase I/II trials with gemtuzumab ozogamicin (Mylotarg(R)) in acute myeloid leukemia. Clin Lymphoma 2002; 2(Suppl 1): S19-23.
179. Trail PA, King HD, Dubowchik GM. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 2003; 52(5): 328-37.
180. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102(4): 1458-65.
181. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: Progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005; 19(2): 176-82.
182. Walter RB, Gooley TA, vanderVelden VHJ, Loken MR, vanDongen JJM, Flowers DA, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007; 109(10): 4168-70.
183. Pai-Scherf LH, Villa J, Pearson D, Watson T, Liu E, Willingham MC, et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res 1999; 5(9): 2311-5.
184. Kreitman RJ. Treatment of Hairy Cell Leukemia (editorial reply). N Engl J Med 2001; 345: 1500.
185. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19(2): 376-88.
186. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, et al. Phase II study of denileukin diftitox for relapsed/ refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 2004; 22(20): 4095-102.
187. Frankel AE, Fleming DR, Hall PD, Powell BL, Black JH, Leftwich C, et al. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res 2003; 9(10 Pt 1): 3555-61.
188. Barbarotto E, Calin GA. Potential therapeutic applications of miRNA-based technology in hematological malignancies. Curr Pharm Des 2008; 14(21): 2040-50.
189. Debbage P. Targeted drugs and nanomedicine: Present and future. Curr Pharm Des 2009; 15(2): 153-72.
190. Zauli G. Editorial: Innovative therapeutical approaches for hematological malignancies based on molecular targeted therapies. Curr Pharm Des 2008; 14(21): 2022.